Rituximab in multiple sclerosis at general hospital level

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Rituximab (RTX) is increasingly used as a disease-modifying therapy for multiple sclerosis (MS).
• Its efficacy and safety outside specialized academic centers remain under-investigated.
• This study evaluates off-label RTX use in a general hospital setting.

Purpose of the Study:

• To assess the effectiveness of rituximab (RTX) for multiple sclerosis (MS) treatment in a general hospital.
• To evaluate the safety profile of RTX in a non-specialized care setting.
• To compare real-world outcomes with those reported from university hospital studies.

Main Methods:

• Retrospective observational study of 83 MS patients receiving at least one RTX infusion.
• Evaluation of clinical disability, annual relapse rates, and new MRI lesions.
• Monitoring of adverse events, including incidence and severity.

Main Results:

• Rituximab showed significant reduction in annual relapse rates (0.38 to 0.05) and new MRI lesions (0.94 to 0.024).
• 86% of relapsing-remitting MS (RRMS) patients and 30% of progressive MS (PMS) patients remained relapse-free.
• Adverse events were mostly mild, with serious events including infections and neutropenia.

Conclusions:

• Rituximab demonstrated comparable efficacy and safety in a general hospital setting to specialized centers.
• Off-label RTX treatment is a viable option for MS management in community hospitals.
• Close vigilance for potential severe adverse events is crucial during RTX therapy.